Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma
Journal of Cutaneous Pathology · 2023
DOI: 10.1111/cup.14438 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cutaneous Pathology, 2023. Verfasst von Hisham F Bahmad und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, Florida, USA. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Nevus, Pigmented, Nevus. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
Background
PRAME (PReferentially expressed Antigen in MElanoma) is a tumor‐associated antigen that has been studied in various cutaneous melanocytic lesions. p16, on the other hand, has been proposed to aid in distinguishing between benign and malignant melanocytic neoplasms. Studies on the diagnostic utility of PRAME and p16 in combination in differentiating nevi from melanoma are limited. We aimed to assess the diagnostic utility of PRAME and p16 in melanocytic tumors and their role in distinguishing between malignant melanomas and melanocytic nevi.
Methods
This is a single‐center retrospective cohort analysis over a 4‐year period (2017–2020). We used the pathological database of malignant melanomas (77 cases) and melanocytic nevi (51 cases) specimens from patients who underwent shave/punch biopsies or surgical excisions and evaluated immunohistochemical staining percentage positivity and intensity for PRAME and p16.
Results
Most malignant melanomas showed positive/diffuse PRAME expression (89.6%); on the other hand, 96.1% of nevi did not express PRAME diffusely. p16 was expressed consistently in nevi (98.0%). However, p16 expression in malignant melanoma was infrequent in our study. PRAME had a sensitivity and specificity of 89.6% and 96.1%, respectively, for melanomas versus nevi; on the other hand, p16 had a sensitivity and specificity of 98.0% and 28.6%, respectively, for nevi versus melanoma. Also, a PRAME+/p16− melanocytic lesion is unlikely to be a nevus where most nevi were PRAME−/p16+.
Conclusion
In conclusion, we confirm the potential utility of PRAME and p16 for distinguishing melanocytic nevi from malignant melanomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine, Mount Sinai Medical Center, Miami Beach, Florida, USA.
- Department of Pathology, Herbert Wertheim College of Medicine, Florida International University, Miami Beach, Florida, USA.
ORCID-Profile: Hisham F Bahmad, Kei Shing Oh, John Alexis
Zitieren
APA
Bahmad, H. F., Oh, K. S., & Alexis, J. (2023). Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma. Journal of Cutaneous Pathology. https://doi.org/10.1111/cup.14438
Vancouver
Bahmad HF, Oh KS, Alexis J. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma. Journal of Cutaneous Pathology. 2023. doi:10.1111/cup.14438
BibTeX
@article{Bahmad2023,
author = {Bahmad, Hisham F and Oh, Kei Shing and Alexis, John},
title = {Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma},
journal = {Journal of Cutaneous Pathology},
year = {2023},
doi = {10.1111/cup.14438}
}
EUVIMED